Julie Cox

Director, Clinical Monitoring

Julie Cox

Director, Clinical Monitoring

Ms. Cox has been engaged in clinical research for eighteen years, principally in industry-sponsored research across all development phases. While she has experience in diverse therapeutic areas, including cardiology, nephrology, metabolic disorders and infectious disease, she has 14 years of experience specific to oncology. Her oncology experience spans Phase I and II solid and liquid tumors and pediatric oncology, and includes the specific indications of NSCLC, renal cell carcinoma, b-cell malignancies, bladder cancer and infantile fibrosarcoma.

For the past ten years, Ms. Cox has been responsible for the training and supervision of clinical monitors within the CRO space, including at Sarah Cannon Development Innovations, an oncology-focused CRO. She has provided training and development specifically of both junior and experienced early phase oncology monitors in both the United States and the European Region. Additionally, Ms. Cox has significant experience in building CRA training curriculums and field assessment practices designed to address the challenges unique to early phase monitoring.

Why Oncology?

“From the first oncology trial I was assigned in 2007 to the present, I have always found oncology research to be the ideal combination of challenging, intellectually engaging and emotionally rewarding. Knowing that I have made some small contribution to ushering an effective cancer treatment through the development process to its approval is remarkably satisfying. I have my own cancer story, as so many of us do, so to be able to be involved in the efforts to conquer it is a special gift.”